The phase 1b KOMET-001 trial, examining the use of KO-539 in patients with relapsed or refractory acute myeloid leukemia, will continue following authorization from the FDA.
Treatment with CA-4948 monotherapy yielded positive safety data and efficacy for patients with relapsed/refractory acute myeloid leukemia and myelodysplastic syndrome; CI-8993 also appeared to show promise in patients with relapsed/refractory solid tumors.
CD123- and CD3-engaging bispecific antibody, APVO436, caused cytokine release syndrome that could be managed through the use of steroids in patients with relapsed/refractory acute myeloid leukemia and myelodysplastic syndrome.
CYNK-001 was recently granted fast track designation by the FDA for the treatment of patients with acute myeloid leukemia.
Preclinical evidence supports further research in combining a menin inhibitor plus targeted therapies, as this may result in superior efficacy for patients with KMT2A-rearranged and NPM1-mutated acute myeloid leukemia.
A cohort study did not identify strong associations between outpatient or inpatient neutropenia management and increased bacteremia incidence, treatment delays, or worse health-related quality of life for pediatric patients with acute myeloid leukemia.
Maintenance oral azacitidine produced a sustained survival benefit over placebo for patients with acute myeloid leukemia in first remission.
A phase 2 study has begun recruiting patients with relapsed/refractory acute myeloid leukemia to test the efficacy of magrolimab.
Pediatric patients with KMT2A-rearranged acute myeloid leukemia who were treated with gemtuzumab ozogamicin plus standard chemotherapy experienced improved event-free survival and a reduced relapsed risk.
Investigators announced positive topline results for the phase 3 QuANTUM-First trial, assessing the use of quizartinib plus chemotherapy for adult patients with newly diagnosed FLT3-ITD–positive acute myeloid leukemia.